Health Condition 1: E669- Obesity, unspecified
Conditions
Interventions
None listed
Sponsors
NIL
Eligibility
Inclusion criteria
Inclusion criteria: The prevalence of the metabolic syndrome will be assessed according to the joint interim statement (2009) of the International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung and Blood Institute (NHLBI), the American Heart Association, the World Heart Federation, the International Atherosclerosis Society, and the International Association for the Study of Obesity (3). Formulated criteria includes when three or more of the following five conditions were present: abdominal obesity (waist circumference > 90 cm in men, > 80 cm in women); serum triglycerides equal to or greater than 150 mg/dl or on treatment (fibrates or nicotinic acid); HDL cholesterol less than 40 mg/dl in men and 50 mg/dl in women or on treatment for low HDL; systolic blood pressure equal to or greater than 135 mm Hg and/or diastolic blood pressure equal to or greater than 85 mm Hg or on antihypertensive medications; and fasting plasma glucose >100 mg/dl or use of hypoglycemic medication.
Exclusion criteria
Exclusion criteria: Patients showing clinical signs, symptoms, or laboratory findings suggestive of ischemic diseases (acute coronary syndrome, acute myocardial infarction, pulmonary embolism), renal diseases, liver diseases and with any type of malignancy were excluded from the study. Other criteria for exclusion were, participants with current or history of alcohol or tobacco intake, oral contraceptives, hormone replacement; patients with, any severe illness, impairment of speech, hearing, vision, or cognition, continuous or periodic use of corticosteroids; pregnant females or unknown pregnancy status or who had given birth within the preceding six weeks, or any significant medical illnesses that prevented participants from adhering to the protocol, lack of approval by physician and patients showing disinterest or refusal to sign the consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LEP -2548 G/A polymorphism and high serum leptin level might confer susceptibility to metabolic syndrome.Timepoint: at baseline; as it is a cross-sectional study | — |
Secondary
| Measure | Time frame |
|---|---|
| high prevalence of LEP -2548 G/A polymorphism in Metabolic syndrome patientsTimepoint: 2 years | — |
Countries
India
Contacts
Public ContactDeepak Parchwani
All India Institute of Medical Sciences, Rajkot
Outcome results
None listed